Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Sparsentan in Kidney disease, Glomerular diseases. The expected timing is based on the latest available company guidance and may change.
EPPIK trial. Presentation at ASN 11/4/23. 10/30/25:- PR No update. 02/19/26:- SPARX Study of FILSPARI in post-transplant recurrent IgAN or FSGS is actively enrolling; additional evidence generation planned in 2026. 05/04/26:- SPARX study on track to complete enrollment in Q2 2026; real-world FILSPARI combo data at NKF. 08/04/26:- SPARX enrollment completed. Data presentations anticipated in 2027.
Verification
Confirm timing and program details against the company announcement or filing.